Literature DB >> 1479604

Predicted and observed sizes of dystrophin in some patients with gene deletions that disrupt the open reading frame.

L V Nicholson1, K M Bushby, M A Johnson, J T den Dunnen, I B Ginjaar, G J van Ommen.   

Abstract

Among 85 patients with Duchenne and Becker muscular dystrophy, 29 were found to have mutations which disrupted the open reading frame for dystrophin. Thus any dystrophin detected in this group of patients should consist of the severely truncated polypeptides that represent prematurely terminated translation products. Dystrophin was detected in blots from 17/29 biopsies and the observed sizes of the polypeptides were compared with predicted sizes calculated in two ways: if translation was terminated at the stop codon generated by each frameshifting deletion, and if the reading frame was restored and translation proceeded. In every case the observed size matched the size predicted on the basis of a restored reading frame. This was in accord with immunocytochemical labelling of scattered dystrophin positive fibres which were found on serial sections labelled with antibodies to both the rod and C-terminal domains. Thus analysis at the protein level supports genetic evidence of exon skipping as a mechanism which restores frameshifting mutations in some fibres.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1479604      PMCID: PMC1016208          DOI: 10.1136/jmg.29.12.892

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  32 in total

1.  Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies.

Authors:  J Chelly; H Gilgenkrantz; M Lambert; G Hamard; P Chafey; D Récan; P Katz; A de la Chapelle; M Koenig; I B Ginjaar
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

2.  Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications.

Authors:  J T Den Dunnen; P M Grootscholten; E Bakker; L A Blonden; H B Ginjaar; M C Wapenaar; H M van Paassen; C van Broeckhoven; P L Pearson; G J van Ommen
Journal:  Am J Hum Genet       Date:  1989-12       Impact factor: 11.025

Review 3.  Dystrophin abnormalities in Duchenne/Becker muscular dystrophy.

Authors:  E P Hoffman; L M Kunkel
Journal:  Neuron       Date:  1989-01       Impact factor: 17.173

4.  Dystrophin diagnosis: comparison of dystrophin abnormalities by immunofluorescence and immunoblot analyses.

Authors:  K Arahata; E P Hoffman; L M Kunkel; S Ishiura; T Tsukahara; T Ishihara; N Sunohara; I Nonaka; E Ozawa; H Sugita
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy.

Authors:  L V Nicholson; M A Johnson; D Gardner-Medwin; S Bhattacharya; J B Harris
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

6.  Immunofluorescence dystrophin study in Duchenne dystrophy through the concomitant use of two antibodies directed against the carboxy-terminal and the amino-terminal region of the protein.

Authors:  M Vainzof; E E Zubrzycka-Gaarn; D Rapaport; M R Passos-Bueno; R C Pavanello; I Pavanello-Filho; M Zatz
Journal:  J Neurol Sci       Date:  1991-02       Impact factor: 3.181

7.  Point mutations in the dystrophin gene.

Authors:  R G Roberts; M Bobrow; D R Bentley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

8.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

9.  The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.

Authors:  M Koenig; A H Beggs; M Moyer; S Scherpf; K Heindrich; T Bettecken; G Meng; C R Müller; M Lindlöf; H Kaariainen; A de la Chapellet; A Kiuru; M L Savontaus; H Gilgenkrantz; D Récan; J Chelly; J C Kaplan; A E Covone; N Archidiacono; G Romeo; S Liechti-Gailati; V Schneider; S Braga; H Moser; B T Darras; P Murphy; U Francke; J D Chen; G Morgan; M Denton; C R Greenberg; K Wrogemann; L A Blonden; M B van Paassen; G J van Ommen; L M Kunkel
Journal:  Am J Hum Genet       Date:  1989-10       Impact factor: 11.025

10.  Differentiation of Duchenne and Becker muscular dystrophy phenotypes with amino- and carboxy-terminal antisera specific for dystrophin.

Authors:  D E Bulman; E G Murphy; E E Zubrzycka-Gaarn; R G Worton; P N Ray
Journal:  Am J Hum Genet       Date:  1991-02       Impact factor: 11.025

View more
  11 in total

1.  Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

2.  Exon skipping and translation in patients with frameshift deletions in the dystrophin gene.

Authors:  T G Sherratt; T Vulliamy; V Dubowitz; C A Sewry; P N Strong
Journal:  Am J Hum Genet       Date:  1993-11       Impact factor: 11.025

3.  Monoclonal antibodies against the muscle-specific N-terminus of dystrophin: characterization of dystrophin in a muscular dystrophy patient with a frameshift deletion of exons 3-7.

Authors:  T T Le; T M Nguyen; D R Love; T R Helliwell; K E Davies; G E Morris
Journal:  Am J Hum Genet       Date:  1993-07       Impact factor: 11.025

4.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

5.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

6.  Frameshift deletions of exons 3-7 and revertant fibers in Duchenne muscular dystrophy: mechanisms of dystrophin production.

Authors:  A V Winnard; J R Mendell; T W Prior; J Florence; A H Burghes
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

Review 7.  Emerging genetic therapies to treat Duchenne muscular dystrophy.

Authors:  Stanley F Nelson; Rachelle H Crosbie; M Carrie Miceli; Melissa J Spencer
Journal:  Curr Opin Neurol       Date:  2009-10       Impact factor: 5.710

8.  Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin.

Authors:  L T Thanh; T M Nguyen; T R Helliwell; G E Morris
Journal:  Am J Hum Genet       Date:  1995-03       Impact factor: 11.025

9.  Revertant fibers in the mdx murine model of Duchenne muscular dystrophy: an age- and muscle-related reappraisal.

Authors:  Sarah R Pigozzo; Lorena Da Re; Chiara Romualdi; Pietro G Mazzara; Eva Galletta; Sue Fletcher; Stephen D Wilton; Libero Vitiello
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

10.  A study on duplications of the dystrophin gene: evidence of a geographical difference in the distribution of breakpoints by intron.

Authors:  F Galvagni; F A Saad; G A Danieli; M Miorin; L Vitiello; M L Mostacciuolo; C Angelini
Journal:  Hum Genet       Date:  1994-07       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.